United States: A Prior Agreement To Outsource Manufacturing Does Not Invalidate A Patent


A patent is invalid if a product embodying the claimed invention was "on sale" more than one year before the filing of an application for the patent. In a recent en banc decision, the Court of Appeals for the Federal Circuit held that, for an invention to be "on sale," a product must be the subject of a commercial sale or offer for sale, and that a commercial sale is one that bears the general hallmarks of a sale pursuant to Section 2-106 of the Uniform Commercial Code, specifically, the passing of title from the seller to the buyer for a price, evidencing relinquishment of interest and control over the product.

Under Supreme Court precedent, parties to a contract are released from their contractual obligations when a contract expires. But a court will compel arbitration under an expired contract if a dispute falls within the scope of the arbitration clause of that contract.

The courts will invalidate a patent, if an applicant commercially sells or offers a product for sale that practices the patent's claims more than one year before filing a patent application. Recently, in The Medicines Co. v. Hospira, Inc., an en banc Federal Circuit held that entering into a contract with a manufacturer to make a patented product does not constitute such an invalidating commercial sale.


The Medicines Company ("MedCo") holds two patents that cover an anticoagulant drug, bivalirudin, which MedCo sells under the trade name Angiomax. These patents were filed in July of 2008. Thus, any commercial sale of bivalirudin prior to July of 2007 would render the patents invalid.

MedCo does not have its own manufacturing facilities so in late 2006, MedCo contracted with Ben Venue to manufacture Angiomax according to the patented formula. By the end of 2006, Ben Venue manufactured three batches of Angiomax, valued at over $20 million. The contract between MedCo and Ben Venue stated that "the solution will be filled for commercial use" and that the manufactured product would be placed on hold until testing was completed. The invoices for each batch that Ben Venue manufactured stated that it would be "released to MedCo for commercial and clinical packaging."

MedCo placed the products into quarantine pending FDA approval. MedCo signed a distribution agreement making ICS the exclusive authorized distributor of Angiomax in the United States and made the quarantined Angiomax available for sale in August 2007.

Before MedCo's patents expired, Hospira filed applications with the FDA to request approval to sell a generic form of the drug. MedCo sued Hospira, alleging that Hospira's FDA applications to manufacture and sell bivalirudin infringed its patents for manufacturing the drug. During litigation, Hospira alleged that the patents were invalid because MedCo sold products manufactured according to the process claimed in the asserted patents when it paid BenVenue to manufacture Angiomax in 2006, and that MedCo offered to sell manufactured Angiomax to ICS for distribution in 2007.

Under the Supreme Court's decision in Pfaff v. Wells, a patent is invalid under the "on-sale bar" rule if a product embodying the claimed invention is both ready for patenting, and commercially offered for sale more than one year before the date of the patent application. Although finding that the claimed was invention ready for patenting more than a year before the application date, the district court found that the invention was not commercially offered for sale prior to the priority date of the patent applications. Specifically, the district court found that the transaction between MedCo and Ben Venue was a sale for contract manufacturing services, and that title to the Angiomax always resided with MedCo. The court also found that because the batches manufactured by Ben Venue were for "validation purposes," they were not made for commercial profit, as required by the "on-sale bar," but for experimental purposes. The district court also held that MedCo's agreement with ICS wasn't an invalidating sale, but rather, the agreement was merely an agreement for ICS to be the sole U.S. distributor of Angiomax—"a contract to enter into a contract." Hospira appealed.

On appeal, Hospira criticized the district court's conclusion that the batches of Angiomax were for experimental purposes, noting that MedCo had not claimed that the Angiomax manufactured by Ben Venue was for experimental use, and that, although title to the manufactured drugs never transferred between MedCo and Ben Venue, MedCo was able to stockpile its product for future sale, thereby enjoying a commercial benefit from the transaction, thus triggering the "on-sale bar" rule.

The En Banc Decision

An en banc Federal Circuit held that for the "on-sale rule" to apply, a product must be the subject of a commercial sale or offer for sale, and that a commercial sale is one that in which title passes from the seller to the buyer for a price, evidencing relinquishment of interest and control over the product. The court found that in this case, no such invalidating commercial sale occurred. The court emphasized that it must focus on activities that constituted sales and offers for sale "in the commercial community." The court found that the transactions between MedCo, Ben Venue, and ICS in 2006 and 2007 did not constitute commercial sales of the patented Angiomax product.

The court first clarified that the sale of manufacturing services by a contract manufacturer to create embodiments of a patented product for the inventor did not constitute a "commercial sale" of the invention. Ben Venue merely sold contract manufacturing services to MedCo—not the patented invention. MedCo paid Ben Venue only about 1% of the ultimate market value of the product that Ben Venue manufactured, and Ben Venue invoiced the sale as manufacturing services.

The court further explained that the sale was only of Ben Venue's manufacturing services since title to the manufactured pharmaceuticals remained with MedCo. Because Ben Venue lacked title, it was not free to use or sell the claimed products or to deliver the patented products to anyone other than MedCo.

The court also explained that "stockpiling" was not improper commercialization that would invalidate the patent. Commercial benefit, even to both parties in a transaction, is not enough to invalidate a patent under the "on-sale bar" rule. Rather, the product "on sale" must be "commercially marketed," and did not include preparation for potential or eventual marketing The court therefore found that MedCo did not market or release its invention to any purchasers by contracting with Ben Venue. The court therefore vacated the panel opinion and remanded to the panel for further proceedings.

Strategy and Conclusion

This case illustrates how patent holders can structure transactions with suppliers before commercially marketing goods and services to avoid potentially negative consequences later on. For example, patent owners outsourcing manufacturing services should retain title to products embodying the patented invention and maintain confidentiality over contracted services.


1 The MedCo  opinion may be found at http://www.finnegan.com/files/upload/LES_Insights_Column/2016/MedicinesCompanyvHospiraInc.pdf.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
15 Nov 2017, Conference, California, United States

Finnegan is a Gold sponsor of the second annual Digital Media & IP Forum, hosted by World Congress.

15 Nov 2017, Conference, London, UK

Finnegan partner Leythem Wall will consider European claim drafting strategy and will lead the Chemical Workshop during a two-day course, hosted by Management Forum.

15 Nov 2017, Seminar, Amsterdam, Netherlands

Finnegan partner Anthony Tridico will lead Forum Institute for Management’s course comparing patent law in the United States and Europe.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.